Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 18/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024683 | 0.92 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL10056640 | 0.84 | NR1H2 (0.40) | NR1H2NR1H3 | |
| SCHEMBL10056591 | 0.84 | TNFRSF1A (0.42) | NR1H2NR1H3 | |
| SCHEMBL10024687 | 0.83 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL10024681 | 0.76 | NR1H2 (0.39) | NR1H2NR1H3 | |
| SCHEMBL19785404 | 0.70 | ALDH1A1 (0.45) | NR1H2 | |
| SCHEMBL13587124 | 0.69 | MEN1 (0.43) | NR1H2 | |
| SCHEMBL16727061 | 0.68 | AKR1C3 (0.57) | — | |
| SCHEMBL16727065 | 0.68 | L3MBTL1 (0.50) | — | |
| SCHEMBL17220690 | 0.67 | NR1H2 (0.62) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097656-B2 | Nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof | Dominion Pharmakine S.L (ES) | 2012-01-17 | — | — | US | disclosed |
| US-20110060038-A1 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | DOMINION PHARMAKINE S.L. (ES) | 2011-03-10 | — | — | US | disclosed |
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | UNIVERSIDAD DEL PAIS VASCO (ES) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | TNNI3, TNNT2, INMT | NR1H2 1668/4885NR1H3 1731/4885SLC16A3 2751/4885 |
| US-20110060038-A1 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | TNNI3, TNNT2, NOS2 | NR1H2 1774/4885NR1H3 1836/4885SLC16A3 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.